

Clinical trials of antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy

TrialResults-center www.trialresultscenter.org

1 albiglutide

Trial	Treatments	Patients	Trials design and methods
albiglutide weekly vs placebo (add on MET)			
Rosenstock (30 mg weekly) , 2009 [NCT00518115] n=31/52 follow-up: 16 weeks	albiglutide 30mg weekly versus placebo	patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy	Parallel groups double-blind US, Mexico, Chile, Dominical republic

References

Rosenstock (30 mg weekly), 2009:

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, , Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. *Diabetes Care* 2009;32:1880-6. [[19592625](#)] [10.2337/dc09-0366](#)

2 bitherapy with MET

Trial	Treatments	Patients	Trials design and methods
dapagliflozin vs placebo (add on MET)			
Bailey (MB102014) , 2010 [NCT00528879] n=NA follow-up: 24 weeks	dapagliflozin (25 mg, n=137; 5 mg, n=137; or 10 mg, n=135) versus placebo	adults with type 2 diabetes who were receiving daily metformin (1500 mg per day) and had inadequate glycaemic control	Parallel groups double-blind

References

Bailey (MB102014), 2010:

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet* 2010 Jun 26;375:2223-2233 [[20609968](#)] [10.1016/S0140-6736\(10\)60407-2](#)

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet* 2010;375:2223-33. [[20609968](#)] [10.1016/S0140-6736\(10\)60407-2](#)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [[26894924](#)]

Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. *BMC Med* 2013;11:43 [[23425012](#)]

3 DPP-4 inhibitors

Trial	Treatments	Patients	Trials design and methods
linagliptin low dose vs linagliptin			
linagliptin 1218.62 <i>ongoing</i> [NCT01012037] n=NA follow-up: 12 weeks	linagliptin low dose 2.5 mg twice daily versus linagliptin medium dose 5 mg once daily	patients with type 2 diabetes mellitus with insufficient glycaemic control with metformin	double-blind Belgium
linagliptin + pioglitazone vs pioglitazone			
linagliptin 1264.3 <i>ongoing</i> [NCT01183013] n=NA follow-up: 30 weeks	linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) linagliptine versus pioglitazone	-	

References

linagliptin 1218.62, 0:

linagliptin 1264.3, 0:

4 DPP-4 inhibitors add on insulin

Trial	Treatments	Patients	Trials design and methods
vildagliptin vs placebo (add on insulin)			
Fonseca , 2007 [NCT00099931] n=144/152 follow-up: 24 weeks	vildagliptin 100 mg daily (add-on to insulin therapy)y) versus placebo (add-on to insulin therapy)y)mag	type 2 diabetes that was inadequately controlled by insulin	double-blind

References

Fonseca, 2007:

Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. *Diabetologia* 2007;50:1148-55
[17387446] [10.1007/s00125-007-0633-0](https://doi.org/10.1007/s00125-007-0633-0)

5 DPP-4 inhibitors add on MET

Trial	Treatments	Patients	Trials design and methods
linagliptin vs glimepiride (add on MET)			

continued...

Trial	Treatments	Patients	Trials design and methods
Gallwitz , 2012 [NCT00622284] n=777/775 follow-up: 104 weeks	linagliptin (5 mg once daily) add-on therapy to preferably >1500 mg metformin versus glimepiride (14 mg) orally once daily add-on therapy to preferably >1500 mg metformin	type 2 diabetes mellitus with insufficient glycaemic control with metformin	Parallel groups double-blind USA
alogliptin vs placebo (add on MET)			
Nauck , 2009 [NCT00286442] n=210/104 follow-up: 26 weeks	alogliptin 12.5 and 25 mg once daily versus placebo	patients whose HbA(1c) levels were inadequately controlled on metformin alone	Parallel groups double-blind
linagliptin vs placebo (add on MET)			
linagliptin 1218.65 <i>ongoing</i> [NCT01215097] n=NA follow-up: 24 weeks	5 mg of Linagliptin administered orally once daily versus placebo (on top metformin)	patients with type 2 diabetes and insufficient glycaemic control with metformin	parallel groups double-blind China
saxagliptin vs placebo (add on MET)			
CV181-066 [NCT00683657] n=NA follow-up:	Saxagliptin versus placebo	Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet And Exercise And A Stable Dose Of Metformin 1500 mg/Day	
CV181-080 [NCT00885378] n=NA follow-up:	2.5 mg Saxagliptin, Twice Daily versus placebo	Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin IR Alone	
DeFronzo , 2009 [NCT00121667] n=191/179 follow-up: 24 weeks	saxagliptin (2.5, 5, or 10 mg once daily) versus placebo	Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone	
Jadzinsky , 2009 [NCT00327015] n=NA follow-up:	saxagliptin versus placebo	treatment-naive patients with type 2 diabetes (T2D) and inadequate glycaemic control	
sitagliptin vs placebo (add on MET)			
Charbonnel , 2006 [NCT0086515] n=NA follow-up:	sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy);	-	
Nauck , 2007 [NCT00094770] n=NA follow-up:	sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy);	-	
Scott** (sit vs pbo on top met) , 2007 n=NA follow-up:	sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy).	patients with type 2 diabetes who were inadequately on MET monotherapy	

continued...

Trial	Treatments	Patients	Trials design and methods
vildagliptin vs placebo (add on MET)			
Ahren , 2004 n=56/51 follow-up: 12 weeks	vildagliptin 50 mg daily (add-on to metformin therapy)j versus placebo (add-on to metformin therapy)mag	patients with type 2 diabetes	double-blind
Bosi , 2007 [NCT00099892] n=185/182 follow-up:	vildagliptin (50 or) 100 mg daily (add-on to metformin therapy)m versus placebo (add-on to metformin therapy)mag	patients with type 2 diabetes inadequately controlled with metformin	double-blind
Goodman , 2009 n=125/122 follow-up: 24 weeks	ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening versus placebo	patients inadequately controlled with metformin	Parallel groups double-blind
saxagliptin vs sitagliptin (add on MET)			
saxagliptin vs sitagliptin n=403/398 follow-up: 18 weeks	saxagliptin 5 mg once daily add on metformin versus sitagliptin 100 mg once daily add on metformin	adults with type 2 diabetes who did not attain adequate glycemic control on metformin therapy alone	Parallel groups
vildagliptin vs Sulfonylurea (add on to MET)			
Ferrannini , 2009 [NCT00106340] n=1396/1393 follow-up: 52 weeks	vildagliptin 50 mg twice daily versus glimepiride titrated up to 6 mg/day	Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%)	Parallel groups double-blind
vildagliptin vs pioglitazone (add on MET)			
Bolli , 2008 [NCT00237237] n=295/281 follow-up:	vildagliptin 100 mg daily (add-on to metformin therapy) versus pioglitazone 30 mg daily (add-on to metformin therapy)j	patients with type 2 diabetes inadequately controlled with metformin monotherapy	double-blind

References

Gallwitz, 2012:

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *Lancet* 2012 Aug 4;380:475-83 [22748821] [10.1016/S0140-6736\(12\)60691-6](https://doi.org/10.1016/S0140-6736(12)60691-6)

Nauck, 2009:

Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. *Int J Clin Pract* 2009;63:46-55 [19125992] [10.1111/j.1742-1241.2008.01933.x](https://doi.org/10.1111/j.1742-1241.2008.01933.x)

linagliptin 1218.65, 0:

CV181-066, :

CV181-080, :

DeFronzo, 2009:

DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care* 2009;32:1649-55 [19478198] [10.2337/dc08-1984](#)

Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. *Postgrad Med* 2011 Jul;123:63-70 [21680990]

Jadzinsky, 2009:

Jadzinsky M, Pftzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. *Diabetes Obes Metab* 2009 Jun;11:611-22 [19515181]

Pftzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. *Diabetes Obes Metab* 2011;13:567-76 [21342412] [10.1111/j.1463-1326.2011.01385.x](#)

Charbonnel, 2006:

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 2006;29:2638-43 [17130197] [10.2337/dc06-0706](#)

Nauck, 2007:

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab* 2007;9:194-205 [17300595] [10.1111/j.1463-1326.2006.00704.x](#)

Seck TL, Engel SS, Williams-Herman DE, Sisk CM, Golm GT, Wang H, Kaufman KD, Goldstein BJ Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. *Diabetes Res Clin Pract* 2011;93:e15-7 [21477878] [10.1016/j.diabres.2011.03.006](#)

Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. *Int J Clin Pract* 2010;64:562-76 [20456211] [10.1111/j.1742-1241.2010.02353.x](#)

Scott (sit vs pbo on top met), 2007:**

Scott R, Loeys T, Davies MJ, Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10:959-69 [18201203] [10.1111/j.1463-1326.2007.00839.x](#)

Ahren, 2004:

Ahrn B, Gomis R, Standl E, Mills D, Schweizer A Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2004;27:2874-80 [15562200]

Bosi, 2007:

Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Care* 2007;30:890-5 [17277036] [10.2337/dc06-1732](#)

Goodman, 2009:

Goodman M, Thurston H, Penman J Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Horm Metab Res* 2009;41:368-73 [19221978] [10.1055/s-0028-1104604](#)

saxagliptin vs sitagliptin, :

Ferrannini, 2009:

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrn B, Byiers S, Shao Q, Dejager S Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2009;11:157-66 [19125777] [10.1111/j.1463-1326.2008.00994.x](#)

Bolli, 2008:

Bolli G, Dotta F, Rochotte E, Cohen SE Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab* 2008;10:82-90 [18034842] [10.1111/j.1463-1326.2007.00820.x](#)

Bolli G, Dotta F, Colin L, Minic B, Goodman M Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab* 2009 Jun;11:589-95 [19515179] [10.1111/j.1463-1326.2008.01023.x](#)

6 DPP-4 inhibitors add on SU

Trial	Treatments	Patients	Trials design and methods
linagliptin vs placebo (add on SU)			
Lewin , 2010 [NCT00819091] n=NA follow-up: 18 weeks	linagliptin 5 mg versus placebo (add-on to sulphonylurea)	patients with type 2 diabetes and insufficient glycaemic control	double-blind

References

Lewin, 2010:

Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Poster no. 821-P, 46th European Association for the Study of Diabetes Annual Meeting, September 2010, Stockholm, Sweden

7 DPP-4 inhibitors add on TZD

Trial	Treatments	Patients	Trials design and methods
saxagliptin vs placebo (add on TZD)			
Hollander [NCT00295633] n=NA follow-up:	saxagliptin (2.5 or 5 mg) versus placebo	patients with type 2 diabetes and inadequate control on thiazolidinedione alone	
sitagliptin vs placebo (on top PIO)			
Rosenstock (sit on top pio vs pbo) , 2006 [NCT00086502] n=NA follow-up:	sitagliptin 100 mg daily (add-on to pioglitazone therapy)sl versus placebo (add-on to pioglitazone therapy);	-	
vildagliptin vs placebo (on top pioglitazone)			
Garber , 2007 [NCT00099853] n=463 follow-up:	vildagliptin 50 or 100 mg daily (add-on to pioglitazone therapy) versus placebo (add-on to pioglitazone therapy)	-	
vildagliptin vs placebo (add on TZD)			
Rosenstock** (vilda + pio vs pio) , 2007 [NCT00101803] n=NA follow-up: 24 weeks	vildagliptin 50 mg or 100 mg daily plus 15 mg or 30 mg pioglitazone daily versus pioglitazone 30 mg daily	drug-naive patients with type 2 diabetes	double-blind

References

Hollander, :

Hollander P, Li J, Allen E, Chen R Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. *J Clin Endocrinol Metab* 2009 Dec;94:4810-9 [19864452]

Hollander PL, Li J, Frederich R, Allen E, Chen R Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res* 2011;8:125-35 [21562064] 10.1177/1479164111404575

Rosenstock (sit on top pio vs pbo), 2006:

Ristic S, Byiers S, Foley J, Holmes D Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab* 2005;7:692-8 [16219012] 10.1111/j.1463-1326.2005.00539.x

Garber, 2007:

Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. *Diabetes Obes Metab* 2007;9:166-74 [17300592] 10.1111/j.1463-1326.2006.00684.x

Rosenstock** (vilda + pio vs pio), 2007:

Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2007;9:175-85 [17300593] 10.1111/j.1463-1326.2006.00698.x

8 glucagon-like peptide analogs

Trial	Treatments	Patients	Trials design and methods
liraglutide other doses vs placebo			
NN2211-1799 <i>ongoing</i> [NCT00620282] n=NA follow-up: 3 months	liraglutide Stepwise dose increase, s.c. injection, once daily versus placebo	subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alon	double-blind USA
tasoglutide vs placebo			
BC21713 (vs placebo) <i>ongoing</i> [NCT00754988] n=NA follow-up:	tasoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly), versus placebo or sitagliptin 100mg once daily in addition to their continued prestudy metformin treatment	patients with type 2 diabetes mellitus inadequately controlled with metformin	parallel groups double-blind USA
tasoglutide 10mg once weekly vs placebo			
Nauck 10 once weekly vs PBO , 2009 [NCT00423501] n=257/49 follow-up: 12 weeks	tasoglutide, either 5, 10, or 20 mg once weekly or 10 or 20 mg once every 2 weeks for 8 weeks versus placebo	patients with type 2 diabetes inadequately controlled with metformin	Parallel groups double-blind
exenatide other doses vs placebo (add on MER+/-SU)			

continued...

Trial	Treatments	Patients	Trials design and methods
Fineman , 2003 n=109 follow-up: 28 days	exenatide 3 regimen (0.08 micro g/kg) for 28 days versus placebo	patients with type 2 diabetes treated with diet and a sulfonylurea and/or metformin	Parallel groups double-blind USA
exenatide 10g/d vs placebo (add on MET)			
DeFronzo 10g/d , 2005 [NCT00039013] n=110/113 follow-up: 30 weeks	Exenatide 1020 g daily versus Placebo on-top of Metformin	patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses	Parallel groups double blind USA
exenatide 20g/d vs placebo (add on MET)			
DeFronzo 20g/d , 2005 [NCT00039013] n=NA follow-up: 30 weeks	Exenatide 1020 g daily versus Placebo on-top of Metformin	patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses	Parallel groups double blind USA
exenatide weekly vs placebo (add on MET)			
Kim , 2007 [NCT00103935] n=30/15 follow-up: 15 weeks	exenatide LAR 0.8 or 2 g daily versus Placebo on-top of metformin	subjects with type 2 diabetes suboptimally controlled with metformin and/or diet and exercise	Parallel groups double blind
liraglutide 1.8mg vs placebo (add on MET)			
LEAD-2 (Nauck) (1.8mg vs placebo) , 2009 [NCT00318461] n=242/122 follow-up: 26 weeks	Liraglutide 1.8 mg daily versus Placebo on-top of Metformin	subjects previously treated with oral antidiabetes therapy	Parallel groups double blind 21 countries
tasoglutide vs placebo (add on MET)			
Ratner (20mg once weekly) , 2010 [NCT00460941] n=97/32 follow-up: 8 weeks (+4wk)	tasoglutide s.c. 20mg once weekly for 8 weeks versus placebo s.c. once weekly on top metformin	subjects with Type 2 diabetes inadequately controlled on metformin alone	Parallel groups double-blind Australia, France, Germany, Mexico, Peru, USA
BC22092 ongoing [NCT00823992] n=NA follow-up:	tasoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) in addition to their prescribed, pre-existing metformin therapy versus placebo	obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy	parallel groups double-blind USA
exenatide 20g/d vs placebo (add on MET+/-SU)			
Gao , 2009 [NCT00324363] n=234/232 follow-up: 16 weeks	exenatide 5 mg then 10 mg twice-daily for 4 and 12 weeks versus placebo	Asian descent with type 2 diabetes and inadequate glycemic control taking metformin alone or Met and sulfonylureas	Parallel groups double-blind 4 countries
exenatide 10g/d vs placebo (add on SU)			

continued...

Trial	Treatments	Patients	Trials design and methods
Buse 10g/d , 2004 [NCT00039026] n=125/123 follow-up: 30 weeks	Exenatide 5g twice daily versus Placebo on-top of SU	patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy	Parallel groups double blind (not adequate) US
exenatide 20g/d vs placebo (add on SU)			
Buse 20g/d , 2004 n=129/123 follow-up: 30 weeks	Exenatide 10g twice daily versus Placebo on-top of SU	patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy	double blind (not adequate) US
liraglutide 1.2mg vs placebo (add on SU)			
LEAD-1 SU (1.2 mg vs placebo) , 2009 [NCT00318422] n=228/115 follow-up: 26 weeks	Liraglutide 1.2 mg daily versus Placebo on-top of sulphonylureas	subjects with Type 2 diabetes	Parallel groups double-blind 21 countries
liraglutide 1.8mg vs placebo (add on SU)			
LEAD-1 SU (1.8 mg vs placebo) , 2009 [NCT00318422] n=234/114 follow-up: 26 weeks	Liraglutide 1.8 mg daily versus Placebo on-top of sulphonylureas	patients with type 2 diabetes	Parallel groups double-blind 21 countries
liraglutide other doses vs placebo (add on SU)			
NN2211-1701 ongoing [NCT00395746] n=NA follow-up: 24 weeks	liraglutide in combination with sulphonylurea versus placebo (add on to SU monotherapy)	subjects with type 2 diabetes	Parallel groups double-blind Japan
liraglutide 1.8mg vs placebo (add on SU+MET)			
LEAD-5 (vs placebo) , 2009 [NCT00331851] n=232/115 follow-up: 26 weeks	Liraglutide 1.8 mg daily versus Placebo on-top of sulphonylureas+metformin	adult patients with type 2 diabetes	Parallel groups double-blind 17 countries
liraglutide other doses vs sitagliptin (add on MET)			
MK-0431-403 ongoing [NCT01296412] n=NA follow-up:	Liraglutide + metformin versus Sitagliptin + metformin	patients with Type 2 Diabetes that is not adequately controlled with metformin alone	parallel groups open
exenatide before lunch and dinner vs exenatide before breakfast and dinner			
Exenatide Trial 10749 n=187/190 follow-up:	exenatide (10 g twice daily) administered subcutaneously before lunch and dinner versus exenatide (10 g twice daily) administered subcutaneously before breakfast and dinner	patients with type 2 Diabetes using oral antidiabetic therapy	Parallel groups open 2 countries
liraglutide other doses vs glibenclamide			

continued...

Trial	Treatments	Patients	Trials design and methods
Seino , 2010 [NCT00393718] n=272/139 follow-up: 24-week	liraglutide 0.9 mg once daily versus glibenclamide once or twice daily at a planned maximum dose of 2.5 mg/day, before or after meals	Japanese subjects with type 2 diabetes, inadequately controlled with diet therapy or oral antidiabetic drug monotherapy	Parallel groups double-blind Japan
liraglutide 1.8mg vs glimepiride (add on MET)			
LEAD-2 (Nauck) (1.8 mg vs glimepiride) , 2009 [NCT00318461] n=242/244 follow-up: 26 weeks	Liraglutide 1.8 mg daily for 26 weeks versus Glimepiride on-top of Metformin	patients with type 3 diabetes previously treated with oral antidiabetes (OAD) therap	Parallel groups double blind 21 countries
exenatide other doses vs insulin glargine (add on MET/SU)			
Trial 8078 n=NA follow-up:	exenatide versus Insulin Glargine	Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin Is the Next Appropriate Therapy	
liraglutide 1.8mg vs insulin glargine (add on SU+MET)			
LEAD-5 (vs Glargine) , 2009 [NCT00331851] n=232/234 follow-up: 26 weeks	Liraglutide 1.8 mg daily versus Glargine on-top of sulphonylureas+metformin	adult patients with type 2 diabetes	Parallel groups open 17 countries
liraglutide other doses vs rosiglitazone (add on SU)			
LEAD-1 SU (1.8 vs rosiglitazone) , 2009 [NCT00318422] n=228/232 follow-up: 26 weeks	Liraglutide 0.6, 1.2 or 1.8 mg daily versus rosiglitazone on-top of sulphonylureas		Parallel groups double-blind 21 countries
liraglutide 1.2mg vs sitagliptin			
Pratley 1.2mg , 2010 [NCT00700817] n=225/219 follow-up: 26 weeks	liraglutide 1.2mg subcutaneously once daily versus oral sitagliptin 100mg once daily	patients with type 2 diabetes who did not have adequate glycemic control with metformin	Parallel groups open Europe, USA, Canada
liraglutide 1.8mg vs sitagliptin			
Pratley 1.8mg , 2010 [NCT00700817] n=221/219 follow-up: 26 weeks	liraglutide 1.8mg subcutaneously once daily versus oral sitagliptin 100mg once daily	patients with type 2 diabetes who did not have adequate glycemic control with metformin	Parallel groups open Europe, USA, Canada

References

NN2211-1799, 0:

BC21713 (vs placebo), 0:

Nauck 10 once weekly vs PBO, 2009:

Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R, Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009;32:1237-43. [19366970] [10.2337/dc08-1961](https://doi.org/10.2337/dc08-1961)

Fineman, 2003:

Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. *Diabetes Care* 2003;26:2370-7 [[12882864](#)]

DeFronzo 10g/d, 2005:

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005;28:1092-100 [[15855572](#)]

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. *Diabetes Obes Metab* 2006;8:436-47 [[16776751](#)] [10.1111/j.1463-1326.2006.00602.x](#)

Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2006;8:419-28 [[16776749](#)] [10.1111/j.1463-1326.2006.00589.x](#)

DeFronzo 20g/d, 2005:

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005;28:1092-100 [[15855572](#)]

Kim, 2007:

Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care* 2007;30:1487-93 [[17353504](#)] [10.2337/dc06-2375](#)

LEAD-2 (Nauck) (1.8mg vs placebo), 2009:

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Dring M, Matthews DR Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care* 2009;32:84-90 [[18931095](#)] [10.2337/dc08-1355](#)

Ratner (20mg once weekly), 2010:

Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R, Safety and tolerability of high doses of taspeglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. *Diabet Med* 2010;27:556-62. [[20536952](#)] [10.1111/j.1464-5491.2010.02990.x](#)

BC22092, 0:**Gao, 2009:**

Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ, Johns D, Northrup J, Brodows R Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. *Diabetes Res Clin Pract* 2009;83:69-76 [[19019476](#)] [10.1016/j.diabres.2008.09.037](#)

Buse 10g/d, 2004:

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004;27:2628-35 [[15504997](#)]

Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. *Diabetes Metab Res Rev* 2006;22:483-91 [[16634116](#)] [10.1002/dmrr.646](#)

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. *Diabetes Obes Metab* 2006;8:436-47 [[16776751](#)] [10.1111/j.1463-1326.2006.00602.x](#)

Buse 20g/d, 2004:

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004;27:2628-35 [[15504997](#)]

LEAD-1 SU (1.2 mg vs placebo), 2009:

Nauck M, Marre M Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. *Postgrad Med* 2009;121:5-15 [[19491535](#)] [10.3810/pgm.2009.05.1997](#)

Marre M, Shaw J, Brndle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med* 2009;26:268-78 [[19317822](#)] [10.1111/j.1464-5491.2009.02666.x](#)

Gallwitz B, Vaag A, Falahati A, Madsbad S Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. *Int J Clin Pract* 2010;64:267-76 [19925617] [10.1111/j.1742-1241.2009.02265.x](https://doi.org/10.1111/j.1742-1241.2009.02265.x)

LEAD-1 SU (1.8 mg vs placebo), 2009:

Marre M, Shaw J, Brndle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med* 2009;26:268-78 [19317822] [10.1111/j.1464-5491.2009.02666.x](https://doi.org/10.1111/j.1464-5491.2009.02666.x)

NN2211-1701, 0:

Hegeds L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. *J Clin Endocrinol Metab* 2011;96:853-60 [21209033] [10.1210/jc.2010-2318](https://doi.org/10.1210/jc.2010-2318)

LEAD-5 (vs placebo), 2009:

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim R Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia* 2009;52:2046-55 [19688338] [10.1007/s00125-009-1472-y](https://doi.org/10.1007/s00125-009-1472-y)

MK-0431-403, 0:

Exenatide Trial 10749, :

Seino, 2010:

Seino Y, Rasmussen MF, Nishida T, Kaku K, Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. *Curr Med Res Opin* 2010;26:1013-22. [20199137] [10.1185/03007991003672551](https://doi.org/10.1185/03007991003672551)

LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009:

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Dring M, Matthews DR Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care* 2009;32:84-90 [18931095] [10.2337/dc08-1355](https://doi.org/10.2337/dc08-1355)

Trial 8078, :

LEAD-5 (vs Glargine), 2009:

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim R Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia* 2009 Oct;52:2046-55 [19688338]

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. *Cardiovasc Diabetol* 2009 Feb 26;8:12 [19245711]

LEAD-1 SU (1.8 vs rosiglitazone), 2009:

Marre M, Shaw J, Brndle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med* 2009;26:268-78 [19317822] [10.1111/j.1464-5491.2009.02666.x](https://doi.org/10.1111/j.1464-5491.2009.02666.x)

Pratley 1.2mg, 2010:

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sndergaard RE, Davies M Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet* 2010 Apr 24;375:1447-1456 [20417856] [10.1016/S0140-6736\(10\)60307-8](https://doi.org/10.1016/S0140-6736(10)60307-8)

Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. *Int J Clin Pract* 2011;65:397-407 [21355967] [10.1111/j.1742-1241.2011.02656.x](https://doi.org/10.1111/j.1742-1241.2011.02656.x)

Pratley 1.8mg, 2010:

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sndergaard RE, Davies M Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet* 2010 Apr 24;375:1447-1456 [20417856] [10.1016/S0140-6736\(10\)60307-8](https://doi.org/10.1016/S0140-6736(10)60307-8)

9 lixisenatide

Trial	Treatments	Patients	Trials design and methods
lixisenatide vs placebo (add on basal insulin)			
GETGOAL-L-ASIA <i>ongoing</i> [NCT00866658] n=NA follow-up: 24 weeks	24 weeks of AVE0010 versus placebo on Top of Basal Insulin +/- Sulfonylurea	Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea	double-blind Japan
lixisenatide vs placebo (add on MET)			
Ratner DRI6012 , 2010 [NCT00299871] n=433/109 follow-up: 13 weeks	subcutaneous lixisenatide doses of 5, 10, 20 or 30 microg once daily or twice daily versus placebo	patients with Type 2 diabetes inadequately controlled with metformin (≥ 1000 mg/day)	Parallel groups double-blind (nature not volume) multinational
GETGOAL-M <i>ongoing</i> [NCT00712673] n=NA follow-up: 24 weeks	-	Type 2 diabetes mellitus insufficiently controlled with metformin	Parallel groups double-blind USA
lixisenatide vs sitagliptin (add on MET)			
EFC10780 , 2010 <i>ongoing</i> [NCT00976937] n=NA follow-up: 24 weeks	Lixisenatide titrated 15-20 g once daily versus Sitagliptin (add-on to Metformin)	Obese Type 2 Diabetic Patients Younger Than 50	Parallel groups double-blind WW

13

References

GETGOAL-L-ASIA, 0:

Ratner DRI6012, 2010:

Ratner RE, Rosenstock J, Boka G Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. *Diabet Med* 2010;27:1024-32 [[20722676](#)] [10.1111/j.1464-5491.2010.03020.x](#)

GETGOAL-M, 0:

EFC10780, 2010:

10 meglitinides (glinides)

Trial	Treatments	Patients	Trials design and methods
repaglinide vs control (add on MET)			
Moses , 1999 n=27/27 follow-up: 12 weeks	prestudy dose of metformin with the addition of repaglinide versus prestudy dose of metformin	patients with type 2 diabetes who had inadequate glycemic control (HbA1c $>7.1\%$) when receiving the antidiabetic agent metformin	Parallel groups open
mitiglinide vs placebo (on top pioglitazone)			

continued...

Trial	Treatments	Patients	Trials design and methods
Kaku , 2009 n=NA follow-up: 16 weeks	additional mitiglinide 5 or 10 mg tid versus placebo on top pioglitazone	Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy	Parallel groups multicenter
nateglinide vs gliclazide (add on MET)			
Ristic , 2006 n=133/129 follow-up: 24 weeks	nateglinide plus metformin versus gliclazide plus metformin	Patients with inadequate glucose control on maximal doses of metformin	Parallel groups double-blind

References

Moses, 1999:

Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 1999;22:119-24 [[10333912](#)]

Moses R Repaglinide in combination therapy with metformin in Type 2 diabetes. *Exp Clin Endocrinol Diabetes* 1999;107 Suppl 4:S136-9 [[10522839](#)] [10.1055/s-0029-1212169](#)

Kaku, 2009:

Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y, Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. *Endocr J* 2009;56:657-64. [[19352048](#)]

Ristic, 2006:

Ristic S, Collober-Maugeais C, Pecher E, Cressier F Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. *Diabet Med* 2006;23:757-62 [[16842480](#)] [10.1111/j.1464-5491.2006.01914.x](#)

Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. *Diabetes Obes Metab* 2007;9:506-11 [[17587393](#)] [10.1111/j.1463-1326.2006.00632.x](#)

11 sulfonylureas G2

Trial	Treatments	Patients	Trials design and methods
glipizide vs glyburide			
Rosenstock , 1993 n=139 follow-up: 4 months	glipizide, 2.5 or 5 mg/day versus glyburide, 1.25 or 2.5 mg/day	elderly patients with NIDDM that was controlled for at least 3 months with oral sulfonylurea therapy	Parallel groups open
glyburide vs placebo			
Vray , 1995 n=NA follow-up:	glibenclamide (2.5 mg X 3/d) versus placebo	type 2 diabetic outpatients, 40-70 years of age, treated by diet alone or oral anti-diabetic drugs	Factorial plan double-blind China

References

Rosenstock, 1993:

Rosenstock J, Corrao PJ, Goldberg RB, Kilo C Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. *Clin Ther* 1993;15:1031-40 [[8111800](#)]

Vray, 1995:

Vray M, Attali JR Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes. Diabete Metab 1995;21:433-9 [8593925]

12 sulfonylureas G2 add on MET

Trial	Treatments	Patients	Trials design and methods
glibenclamide vs control (add on MET)			
Marre (ass) , 2002 n=NA follow-up: 16 weeks	metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) <or = 7 mmol/l versus metformin 500 mg,	patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy	Parallel groups double-blind
glipizide vs control (add on MET)			
Goldstein n=NA follow-up:	glipizide/metformin 5/500 mg tablets versus metformin 500-mg	patients with type 2 DM that is uncontrolled by at least half the maximum labeled daily dose of a sulfonylurea	Cross over open
glyburide vs control (add on MET)			
Blonde , 2002 n=NA follow-up: 16 weeks	glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162) versus metformin 500 mg	patients with inadequate glycaemic control on at least half-maximal dose of sulphonylurea	Parallel groups double-blind

15

References

Marre (ass), 2002:

Marre M, Howlett H, Lehert P, Allavoine T Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80 [12147149]

Goldstein, :

Goldstein BJ, Pans M, Rubin CJ Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003;25:890-903 [12852706]

Blonde, 2002:

Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002;4:368-75 [12406033]

13 sulfonylureas G3 add on insulin

Trial	Treatments	Patients	Trials design and methods
glimepiride vs placebo (add on insulin)			
Riddle , 1994 <i>unpublished</i> n=72/73 follow-up:	Glimepiride (16 mg/day) plus insulin versus insulin plus placebo	obese patients with type 2 diabetes insufficiently controlled by full dosages of sulphonylureas (glimepiride titrated up to 8mg twice daily and with laboratory-monitored FPG of 10 to 16 mmol/L (180 to 300 mg/dl))	

References

Riddle, 1994:

Riddle M, Schneider J, Glimepiride CG. Glimepiride (HOE490) combined with insulin for NIDDM secondary failures to sulfonylurea monotherapy: results of a multicenter trial [abstract]. 15th Int Diab Fed Congr 1994: 418

14 sulfonylureas G3 add on MET

Trial	Treatments	Patients	Trials design and methods
glimepiride vs placebo (add on MET)			
Charpentier , 2001 n=NA follow-up:	metformin and glimepiride versus metformin	Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily	double-blind France

References

Charpentier, 2001:

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-34 [11678974]

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S, Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-34. [11678974]

15 sulfonylureas G3 monotherapy

Trial	Treatments	Patients	Trials design and methods
glimepiride vs gliclazide or glibenclamide			
Inukai , 2005 n=172 follow-up: 6 months	glimepiride versus gliclazide or glibenclamide	Japanese type 2 diabetic patients (HbA1C >or = 7.0%), maintained on a conventional SU	Parallel groups open Japan

References

Inukai, 2005:

Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama S Efficacy of glimepiride in Japanese type 2 diabetic subjects. *Diabetes Res Clin Pract* 2005;68:250-7 [[15936468](#)] [10.1016/j.diabres.2004.10.002](#)

Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama S, Efficacy of glimepiride in Japanese type 2 diabetic subjects. *Diabetes Res Clin Pract* 2005;68:250-7. [[15936468](#)] [10.1016/j.diabres.2004.10.002](#)

Entry terms: glimeripide, glimepiride, glymepiride, HOE 490, HOE-490, Roname, Amaryl, Amarel, hydroxyglimepiride, hydroxy-glimepiride, , dapagliflozin, dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148,

16 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.